Small pharmaceutical company plans on reviving failed cholesterol medication

DalCor Pharmaceuticals has raised $150 million to launch a clinical trial involving a cholesterol drug (dalcetrapib) that did not prevent MI and strokes in a previous phase 3 trial, the Wall Street Journal reports. 

Roche Holding AG discontinued manufacturing dalcetrapib following the failed study. DalCor plans on enrolling patients with a favorable genetic profile.

For more, check out the link below: